Plus Therapeutics (PSTV) Invested Capital (2016 - 2025)
Plus Therapeutics (PSTV) has disclosed Invested Capital for 16 consecutive years, with $5.1 million as the latest value for Q3 2025.
- On a quarterly basis, Invested Capital rose 368.54% to $5.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.1 million, a 368.54% increase, with the full-year FY2024 number at -$5.7 million, down 315.26% from a year prior.
- Invested Capital was $5.1 million for Q3 2025 at Plus Therapeutics, up from $3.0 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $21.5 million in Q3 2021 to a low of -$23.6 million in Q1 2025.
- A 5-year average of $5.6 million and a median of $7.2 million in 2023 define the central range for Invested Capital.
- Biggest YoY gain for Invested Capital was 368.54% in 2025; the steepest drop was 1795.83% in 2025.
- Plus Therapeutics' Invested Capital stood at $21.5 million in 2021, then tumbled by 62.56% to $8.1 million in 2022, then tumbled by 67.37% to $2.6 million in 2023, then plummeted by 315.26% to -$5.7 million in 2024, then surged by 189.34% to $5.1 million in 2025.
- Per Business Quant, the three most recent readings for PSTV's Invested Capital are $5.1 million (Q3 2025), $3.0 million (Q2 2025), and -$23.6 million (Q1 2025).